{"title":"类风湿关节炎合并肺气肿患者抗牙龈卟啉单胞菌脂多糖抗体的研究。","authors":"Shomi Oka, Takashi Higuchi, Kota Shimada, Misuzu Fujimori, Atsushi Hashimoto, Akiko Komiya, Koichiro Saisho, Norie Yoshikawa, Michita Suzuki, Toshihiro Matsui, Naoshi Fukui, Kiyoshi Migita, Shigeto Tohma, Hiroshi Furukawa","doi":"10.3389/fmed.2025.1654271","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Lung diseases that are chronic (emphysema [EMP], airway disease, interstitial lung disease) can complicate rheumatoid arthritis (RA) as extra-articular manifestations. Anti-<i>Porphyromonas gingivalis</i> (<i>P. gingivalis</i>) antibody (Ab) has been analyzed for the diagnosis of periodontal disease and RA patients showed increased anti-<i>P. gingivalis</i> Ab levels. However, amounts of anti-<i>P. gingivalis</i> Ab in RA complicated with chronic lung disease (CLD) are unknown. We measured anti-<i>P. gingivalis</i> Ab in cases of RA with CLD.</p><p><strong>Methods: </strong>Anti-<i>P. gingivalis</i> lipopolysaccharide (LPS) Ab were measured in RA patient sera by enzyme immunoassay.</p><p><strong>Results: </strong>Anti-<i>P. gingivalis</i> LPS Ab levels in RA with EMP were significantly lower than in RA cases without CLD (<i>P</i> = 0.0190, mean ± standard deviation [SD], 32.7 ± 64.2 [×10<sup>3</sup>U/mL] vs. 403.5 ± 2552.7 [×10<sup>3</sup>U/mL]). Multiple logistic regression analyses revealed the independence of this association. Anti-<i>P. gingivalis</i> LPS Ab amounts were increased in RA without CLD (<i>P</i> = 0.0412) compared with healthy controls (77.6 ± 183.7 [×10<sup>3</sup>U/mL]).</p><p><strong>Conclusion: </strong>Anti-<i>P. gingivalis</i> LPS Ab levels in RA with EMP were lower compared with RA without CLD. Citrullinated peptides were mainly generated in the lungs of RA with EMP and the oral cavity of RA without CLD, suggesting the heterogeneity of RA.</p>","PeriodicalId":12488,"journal":{"name":"Frontiers in Medicine","volume":"12 ","pages":"1654271"},"PeriodicalIF":3.1000,"publicationDate":"2025-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12497748/pdf/","citationCount":"0","resultStr":"{\"title\":\"Anti-<i>Porphyromonas gingivalis</i> lipopolysaccharide antibody in rheumatoid arthritis patients with emphysema.\",\"authors\":\"Shomi Oka, Takashi Higuchi, Kota Shimada, Misuzu Fujimori, Atsushi Hashimoto, Akiko Komiya, Koichiro Saisho, Norie Yoshikawa, Michita Suzuki, Toshihiro Matsui, Naoshi Fukui, Kiyoshi Migita, Shigeto Tohma, Hiroshi Furukawa\",\"doi\":\"10.3389/fmed.2025.1654271\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>Lung diseases that are chronic (emphysema [EMP], airway disease, interstitial lung disease) can complicate rheumatoid arthritis (RA) as extra-articular manifestations. Anti-<i>Porphyromonas gingivalis</i> (<i>P. gingivalis</i>) antibody (Ab) has been analyzed for the diagnosis of periodontal disease and RA patients showed increased anti-<i>P. gingivalis</i> Ab levels. However, amounts of anti-<i>P. gingivalis</i> Ab in RA complicated with chronic lung disease (CLD) are unknown. We measured anti-<i>P. gingivalis</i> Ab in cases of RA with CLD.</p><p><strong>Methods: </strong>Anti-<i>P. gingivalis</i> lipopolysaccharide (LPS) Ab were measured in RA patient sera by enzyme immunoassay.</p><p><strong>Results: </strong>Anti-<i>P. gingivalis</i> LPS Ab levels in RA with EMP were significantly lower than in RA cases without CLD (<i>P</i> = 0.0190, mean ± standard deviation [SD], 32.7 ± 64.2 [×10<sup>3</sup>U/mL] vs. 403.5 ± 2552.7 [×10<sup>3</sup>U/mL]). Multiple logistic regression analyses revealed the independence of this association. Anti-<i>P. gingivalis</i> LPS Ab amounts were increased in RA without CLD (<i>P</i> = 0.0412) compared with healthy controls (77.6 ± 183.7 [×10<sup>3</sup>U/mL]).</p><p><strong>Conclusion: </strong>Anti-<i>P. gingivalis</i> LPS Ab levels in RA with EMP were lower compared with RA without CLD. Citrullinated peptides were mainly generated in the lungs of RA with EMP and the oral cavity of RA without CLD, suggesting the heterogeneity of RA.</p>\",\"PeriodicalId\":12488,\"journal\":{\"name\":\"Frontiers in Medicine\",\"volume\":\"12 \",\"pages\":\"1654271\"},\"PeriodicalIF\":3.1000,\"publicationDate\":\"2025-09-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12497748/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Frontiers in Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3389/fmed.2025.1654271\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q1\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fmed.2025.1654271","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
Anti-Porphyromonas gingivalis lipopolysaccharide antibody in rheumatoid arthritis patients with emphysema.
Objective: Lung diseases that are chronic (emphysema [EMP], airway disease, interstitial lung disease) can complicate rheumatoid arthritis (RA) as extra-articular manifestations. Anti-Porphyromonas gingivalis (P. gingivalis) antibody (Ab) has been analyzed for the diagnosis of periodontal disease and RA patients showed increased anti-P. gingivalis Ab levels. However, amounts of anti-P. gingivalis Ab in RA complicated with chronic lung disease (CLD) are unknown. We measured anti-P. gingivalis Ab in cases of RA with CLD.
Methods: Anti-P. gingivalis lipopolysaccharide (LPS) Ab were measured in RA patient sera by enzyme immunoassay.
Results: Anti-P. gingivalis LPS Ab levels in RA with EMP were significantly lower than in RA cases without CLD (P = 0.0190, mean ± standard deviation [SD], 32.7 ± 64.2 [×103U/mL] vs. 403.5 ± 2552.7 [×103U/mL]). Multiple logistic regression analyses revealed the independence of this association. Anti-P. gingivalis LPS Ab amounts were increased in RA without CLD (P = 0.0412) compared with healthy controls (77.6 ± 183.7 [×103U/mL]).
Conclusion: Anti-P. gingivalis LPS Ab levels in RA with EMP were lower compared with RA without CLD. Citrullinated peptides were mainly generated in the lungs of RA with EMP and the oral cavity of RA without CLD, suggesting the heterogeneity of RA.
期刊介绍：
Frontiers in Medicine publishes rigorously peer-reviewed research linking basic research to clinical practice and patient care, as well as translating scientific advances into new therapies and diagnostic tools. Led by an outstanding Editorial Board of international experts, this multidisciplinary open-access journal is at the forefront of disseminating and communicating scientific knowledge and impactful discoveries to researchers, academics, clinicians and the public worldwide.
In addition to papers that provide a link between basic research and clinical practice, a particular emphasis is given to studies that are directly relevant to patient care. In this spirit, the journal publishes the latest research results and medical knowledge that facilitate the translation of scientific advances into new therapies or diagnostic tools. The full listing of the Specialty Sections represented by Frontiers in Medicine is as listed below. As well as the established medical disciplines, Frontiers in Medicine is launching new sections that together will facilitate
- the use of patient-reported outcomes under real world conditions
- the exploitation of big data and the use of novel information and communication tools in the assessment of new medicines
- the scientific bases for guidelines and decisions from regulatory authorities
- access to medicinal products and medical devices worldwide
- addressing the grand health challenges around the world
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
